Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Toulouse
Clinical trial register · France

Clinical Trials in Toulouse, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC
9697
Studies in scope
all four open statuses
6025
Recruiting now
open to new participants
1033
Lead sponsors
across recruiting studies
Top sites
Paris 64 Bordeaux 62 Montpellier 61 Lyon 60 Marseille 58
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital, Toulouse170 AstraZeneca32 Merck Sharp & Dohme LLC32 Novartis Pharmaceuticals30 AbbVie26 Clear sponsor filter
Site location
Paris64 Bordeaux62 Montpellier61 Lyon60 Marseille58
All 106 locations
Target enrolment
to

Trials with a site in Toulouse

32 of 9697 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
AstraZeneca
Phase 3
750
Lille, Nantes, Paris, Toulouse
2026-09-24
Recruiting
AstraZeneca
Phase 3
1,072
Bordeaux, Paris, Strasbourg, Toulouse
2026-08-31
Recruiting
AstraZeneca
Phase 3
2,500
Bobigny, Colmar, Dijon, Paris, Pessac, Pierre-Bénite, Thionville, Toulouse
2026-08-19
Recruiting
AstraZeneca
Phase 3
750
Lille, Nantes, Paris, Poitiers, Toulouse
2026-06-26
Active, closed
AstraZeneca
Phase 2
326
Créteil, Marseille, Rennes, Toulouse
2026-06-11
Recruiting
AstraZeneca
Phase 3
508
Lille, Nantes, Paris, Pierre-Bénite, Poitiers, Toulouse
2026-02-23
Recruiting
AstraZeneca
Phase 2
435
Brest, Créteil, Marseille, Montpellier, Paris, Pessac, Strasbourg, Toulouse
2025-11-06
Recruiting
AstraZeneca
Phase 3
400
Boulogne-Billancourt, Lyon, Marseille, Saint-Herblain, Toulouse
2025-10-31
Recruiting
AstraZeneca
Phase 1
72
Bordeaux, Montpellier, Nancy, Paris, Strasbourg, Toulouse
2025-05-01
Active, closed
AstraZeneca
Phase 3
181
Le Kremlin-Bicêtre, Marseille, Nantes, Pierre-Bénite, Poitiers, Toulouse
2024-12-03
Active, closed
AstraZeneca
Phase 3
339
Bois-Guillaume, Dijon, Lyon, Montivilliers, Nantes, Paris, Poitiers, Toulouse
2024-06-29
Recruiting
AstraZeneca
Phase 3
100
Bordeaux, Bron, Le Kremlin-Bicêtre, Lille, Toulouse
2024-03-14
Active, closed
AstraZeneca
Phase 2
142
La Tronche, Marseille, Montpellier, Mulhouse, Paris, Pessac, Poitiers, Toulouse
2024-02-22
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Caen, Marseille, Nantes, Paris, Pierre-Bénite, Toulouse
2023-12-29
Recruiting
AstraZeneca
Phase 3
1,145
Avignon, Bordeaux, Le Mans, Lyon, Nice, Saint-Herblain, Toulouse, Villejuif
2023-12-14
Active, closed
AstraZeneca
Phase 3
760
Marseille, Montpellier, Pessac, Rennes, Strasbourg, Toulouse, Villejuif
2023-12-04
Recruiting
AstraZeneca
Phase 3
625
Lille, Lyon, Montpellier, Paris, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif
2023-11-23
Active, closed
AstraZeneca
Phase 3
314
Bordeaux, Brest, Paris, Rennes, Strasbourg, Toulouse
2023-11-08
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
392
Toulouse, Villejuif
2023-07-11
Active, closed
AstraZeneca
Phase 3
363
Aurillac, Bordeaux, Marseille, Paris, Strasbourg, Toulouse
2022-02-15
Active, closed
AstraZeneca
Phase 3
145
Créteil, Lyon, Toulouse
2021-11-19
Active, closed
AstraZeneca
Phase 3
148
Bordeaux, Quimper, Toulouse, Villejuif
2021-10-28
Active, closed
AstraZeneca
Phase 3
454
Bordeaux, Dijon, Le Mans, Lyon, Marseille, Nantes, Toulouse, Villejuif
2021-10-28
Active, closed
AstraZeneca
Phase 3
732
Bezannes, Bordeaux, Lille, Lyon, Montpellier, Plérin, Toulouse, Villejuif
2021-10-18
Active, closed
AstraZeneca
Phase 1/2
212
Dijon, Toulouse
2021-09-14
Active, closed
AstraZeneca
Phase 3
134
Lille, Pessac, Strasbourg, Suresnes, Toulouse
2020-07-20
Active, closed
AstraZeneca
Phase 3
140
Dijon, Marseille, Montpellier, Nantes, Paris, Suresnes, Toulouse
2019-10-29
Active, closed
AstraZeneca
Phase 3
724
Bron, Dijon, Lyon, Nantes, Pierre-Bénite, Toulouse, Villejuif
2019-03-06
Active, closed
AstraZeneca
Phase 3
724
Bobigny, Clichy, Grenoble, Montpellier, Nice, Paris, Pessac, Toulouse
2018-11-30
Active, closed
AstraZeneca
Phase 1
117
Bordeaux, Caen, Lyon, Marseille, Saint-Herblain, Toulouse
2016-12-28
Active, closed
AstraZeneca
Phase 3
1,126
Bordeaux, Caen, Lyon, Marseille, Paris, Poitiers, Suresnes, Toulouse
2015-11-02
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Bordeaux, Caen, Lyon, Nantes, Paris, Pierre-Bénite, Saint-Cloud, Toulouse
2013-09-03
Rows per page Showing 1–32 of 32
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 October 2026. https://priyalifescience.com/clinical-trials-france/city/toulouse

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 32 of those studies with a site in Toulouse that also match the filters currently applied.

How many clinical trials are recruiting in Toulouse?

13 of the 32 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Toulouse), 32 studies
PhaseStudiesRecruitingShare
Phase 324975%
Phase 1/2329.4%
Phase 2319.4%
Phase 1216.3%

Most active sponsors

Lead sponsors with the most studies (Toulouse)
Lead sponsorStudiesRecruiting
AstraZeneca3213
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.